Archive

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical...

Full releases >>

First Patient enrolled in Europe for the clinical study COMPETE at the University Hospital Marburg, Germany.

COMPETE to investigate a broad...

Full releases >>

ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution.

Meeting attended by over 60 investigators as...

Full releases >>

With a 174 % growth, ITM Isotopen Technologien München AG is one of the 50 winners of the Deloitte Technology Fast 50 Award 2017

Full releases >>

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the enrollment of the first patient recruited...

Full releases >>

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted...

Full releases >>

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the Committee for Medicinal Products for Human...

Full releases >>

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and...

Full releases >>

Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company

Full releases >>

The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone...

Full releases >>